News - Roche, Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 30 results

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA

22-10-2013

Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis

04-07-2013

Belgium's leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted…

Anti-Arthritics/RheumaticsLicensingolokizumabPharmaceuticalR-PharmaRoActemraRocheUCB

Chugai gains Japanese approval for Perjeta and Bonviva

28-06-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis

20-06-2013

The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso

10-06-2013

French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Proposal to list Roche's Neulastim and Actemra in New Zealand

24-05-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of a proposal to list…

ActemraAnti-Arthritics/RheumaticsAsia-PacificNeulastimOncologyPharmaceuticalPricingRegulationRoche

New Zealand considers listing of Neulastim and Actemra

12-04-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…

ActemraAnti-Arthritics/RheumaticsAsia-PacificBiotechnologyNeulastimOncologyPharmaceuticalPricingRegulationRoche

Roche's RoActemra shows superiority to Humira in rheumatoid arthritis

18-03-2013

Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug…

Anti-Arthritics/RheumaticsBiotechnologyHumiraPharmaceuticalResearchRoActemraRoche

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR

07-06-2012

Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearchRoActemraRoche

EMA confirms Roche's MabThera made at Vacaville site poses no health risk

28-05-2012

Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines…

Anti-Arthritics/RheumaticsBiotechnologyMabTheraOncologyPharmaceuticalRegulationRoche

Mylan settles over Brovana; launches generic Boniva in UK and Italy

27-05-2012

US generic drugs major Mylan (Nasdaq: MYL) has entered into an agreement with Sunovion Pharmaceuticals,…

Anti-Arthritics/RheumaticsBonivaBrovanaDainippon Sumitomo PharmaEuropeGenericsMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsRespiratory and PulmonaryRocheSunovion

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin

27-04-2012

There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

FDA approves first generics of Roche osteo drug Boniva

20-03-2012

The US Food and Drug Administration yesterday approved the first generic versions of Boniva (ibandronate)…

Anti-Arthritics/RheumaticsApotexBonivaGenericsMylan LaboratoriesNorth AmericaOrchid HealthcareRegulationRoche

NICE backs Roche RoActemra, but with PAS discount

22-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today recommended…

Anti-Arthritics/RheumaticsEuropePharmaceuticalPricingRegulationRoActemraRoche

Mixed NICE views on Faslodex and RoActemra

14-12-2011

There was mixed news this morning from the UK’s National Institute for Health and Clinical Excellence…

Anti-Arthritics/RheumaticsAstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulationRoActemraRoche

1 to 25 of 30 results

Back to top